Ayala Pharmaceuticals

OverviewSuggest Edit

Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company developing medicines for cancers that are genetically defined. The company offers AL101 and AL102 gamma-secretase inhibitors, with clinical and nonclinical studies underway in both solid tumors (AL101) and hematologic malignancies (AL102).

TypePrivate
Founded2017
HQWilmington, US
Websiteayalapharma.com

Latest Updates

Employees (est.) (Mar 2020)28(+4%)

Key People/Management at Ayala Pharmaceuticals

Roni Mamluk

Roni Mamluk

CEO
Gary Gordon

Gary Gordon

Chief Medical Officer
Dana Gelbaum

Dana Gelbaum

Chief Business Officer
David Caron

David Caron

VP CMC
Joel Kaye

Joel Kaye

VP Research and Nonclinical Development
Irit Klipper-Avni

Irit Klipper-Avni

VP Human Resources
Show more

Ayala Pharmaceuticals Office Locations

Ayala Pharmaceuticals has offices in Wilmington and Rehovot
Wilmington, US (HQ)
1313 N Market St #5100
Rehovot, IL
Prof. Hillel ve-Khanan Oppenheimer St 4
Show all (2)

Ayala Pharmaceuticals Financials and Metrics

Summary Metrics

Founding Date

2017

Ayala Pharmaceuticals total Funding

$47 m

Ayala Pharmaceuticals latest funding size

$30 m

Time since last funding

10 months ago

Ayala Pharmaceuticals investors

Ayala Pharmaceuticals's latest funding round in May 2019 was reported to be $30 m. In total, Ayala Pharmaceuticals has raised $47 m
Show all financial metrics

Ayala Pharmaceuticals Online and Social Media Presence

Embed Graph

Ayala Pharmaceuticals News and Updates

ArcherDX and Ayala Pharmaceuticals Announce Strategic Companion Diagnostic Collaboration

BOULDER, Colo., July 8, 2019 /PRNewswire/ -- ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough solutions that advance the application of personalized genomic medicine and Ayala Pharmaceuticals, a clinical stage precision oncology company dedicated to...

Ayala Pharmaceuticals Blogs

Ayala Pharmaceuticals Granted U.S. FDA Fast Track Designation for AL101 for the Treatment of Recurrent or Metastatic Adenoid Cystic Carcinoma

REHOVOT, Israel & WILMINGTON, Del., March 2, 2020 – (BUSINESS WIRE) – Ayala Pharmaceuticals, Inc., a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that the U.S. Food a…

Ayala Pharmaceuticals Presents Encouraging Preliminary Safety and Efficacy Data in Patients with Recurrent/Metastatic Adenoid Cystic Carcinoma with Progressing Disease and Notch Activating Mutations from Ongoing Phase 2 Clinical Trial at ESMO

- 22% Response Rate; 61% Disease Control Observed - REHOVOT, Israel & WILMINGTON, Del., September 30, 2019 – (BUSINESS WIRE) – Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with cancer, today announced …

Ayala Pharmaceuticals Announces Presentation at the European Society for Medical Oncology (ESMO)

REHOVOT, Israel & WILMINGTON, Del., September 19, 2019 – (BUSINESS WIRE) – Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers, today announced that a poster will be presented…

Ayala Pharmaceuticals to Present at 2019 Ladenburg Thalmann Healthcare Conference

REHOVOT, Israel & WILMINGTON, Del., September 17, 2019 – (BUSINESS WIRE) – Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers, today announced that Roni Mamluk, Ph.D., Chief …

Ayala Pharmaceuticals Announces Appointment of Gary Gordon, M.D., Ph.D., as Chief Medical Officer

REHOVOT, Israel & WILMINGTON, Del., September 9, 2019 – (BUSINESS WIRE) – Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers, today announced the appointment of Gary Gordon, …

Ayala Pharmaceuticals to Present at Raymond James Life Sciences and MedTech Conference

REHOVOT, Israel & WILMINGTON, Del.--(BUSINESS WIRE)--Ayala Pharmaceuticals, Inc., a clinical-stage company developing medicines for cancers that are genetically defined, today announced that Roni Mamluk, Ph.D., Chief Executive Officer of Ayala, will present at the Raymond James Life Sciences and…

Ayala Pharmaceuticals Frequently Asked Questions

  • When was Ayala Pharmaceuticals founded?

    Ayala Pharmaceuticals was founded in 2017.

  • Who are Ayala Pharmaceuticals key executives?

    Ayala Pharmaceuticals's key executives are Roni Mamluk, Gary Gordon and Dana Gelbaum.

  • How many employees does Ayala Pharmaceuticals have?

    Ayala Pharmaceuticals has 28 employees.

  • Who are Ayala Pharmaceuticals competitors?

    Competitors of Ayala Pharmaceuticals include NextCure, Prelude Therapeutics and Shanghai Henlius Biotech.

  • Where is Ayala Pharmaceuticals headquarters?

    Ayala Pharmaceuticals headquarters is located at 1313 N Market St #5100, Wilmington.

  • Where are Ayala Pharmaceuticals offices?

    Ayala Pharmaceuticals has offices in Wilmington and Rehovot.

  • How many offices does Ayala Pharmaceuticals have?

    Ayala Pharmaceuticals has 2 offices.